Infect. Immun., Mar 1997, 1045-1052, Vol 65, No. 3
Copyright © 1997, American Society for Microbiology

Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys

SJ Devi, WD Zollinger, PJ Snoy, JY Tai, P Costantini, F Norelli, R Rappuoli and CE Frasch
Division of Bacterial Products, Office of Vaccine Research and Review, U.S. Food and Drug Administration, Rockville, Maryland 20852, USA.

We reported the first use of group B meningococcal conjugate vaccines in a nonhuman primate model (S. J. N. Devi, C. E. Frasch, W. Zollinger, and P. J. Snoy, p. 427-429, in J. S. Evans, S. E. Yost, M. C. J. Maiden, and I. M. Feavers, ed., Proceedings of the Ninth International Pathogenic Neisseria Conference, 1994). Three different group B Neisseria meningitidis capsular polysaccharide (B PS)-protein conjugate vaccines and an Escherichia coli K92 capsular polysaccharide-tetanus toxoid (K92-TT) conjugate vaccine are here evaluated for safety and relative immunogenicities in juvenile rhesus monkeys with or without adjuvants. Monkeys were immunized intramuscularly with either B PS- cross-reactive material 197 conjugate, B PS-outer membrane vesicle (B- OMV) conjugate, or N-propionylated B PS-outer membrane protein 3 (N-pr. B-OMP3) conjugate vaccine with or without adjuvants at weeks 0, 6, and 14. A control group of monkeys received one injection of the purified B PS alone, and another group received three injections of B PS noncovalently complexed with OMV. Antibody responses as measured by enzyme-linked immunosorbent assay varied among individual monkeys. All vaccines except B PS and the K92-TT conjugate elicited a twofold or greater increase in total B PS antibodies after one immunization. All vaccines, including the K92-TT conjugate, elicited a rise in geometric mean B PS antibody levels of ninefold or more over the preimmune levels following the third immunization. Antibodies elicited by N-pr. B-OMP3 and B-OMV conjugates were directed to the N-propionylated or to the spacer-containing B PS antigens as well as to the native B PS complexed with methylated human serum albumin. None of the vaccines caused discernible safety-related symptoms.

This article has been cited by other articles:

• Beernink, P. T., Granoff, D. M. (2008). Bactericidal Antibody Responses Induced by Meningococcal Recombinant Chimeric Factor H-Binding Protein Vaccines. Infect. Immun. 76: 2568-2575 [Abstract] [Full Text]  
• de Jonge, M. I., Vidarsson, G., van Dijken, H. H., Hoogerhout, P., van Alphen, L., Dankert, J., van der Ley, P. (2003). Functional Activity of Antibodies against the Recombinant OpaJ Protein from Neisseria meningitidis. Infect. Immun. 71: 2331-2340 [Abstract] [Full Text]  
• Moe, G. R., Tan, S., Granoff, D. M. (1999). Differences in Surface Expression of NspA among Neisseria meningitidis Group B Strains. Infect. Immun. 67: 5664-5675 [Abstract] [Full Text]  
• Granoff, D. M., Bartoloni, A., Ricci, S., Gallo, E., Rosa, D., Ravenscroft, N., Guarnieri, V., Seid, R. C., Shan, A., Usinger, W. R., Tan, S., McHugh, Y. E., Moe, G. R. (1998). Bactericidal Monoclonal Antibodies That Define Unique Meningococcal B Polysaccharide Epitopes That Do Not Cross-React with Human Polysialic Acid. J. Immunol. 160: 5028-5036 [Abstract] [Full Text]